Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmanex

This article was originally published in The Tan Sheet

Executive Summary

Cholestin marketer secures $11 mil. in new equity financing from a group of Swiss banks that will assist the Simi Valley, Calif. firm with the launch and marketing support of its 31-item Premium Self-Care Botanical Extracts line, which began shipping in June. The company recently agreed with FDA to modify certain structure/function claims for some of the single-ingredient products, including goldenseal, evening primrose oil and cranberry in response to an agency "courtesy" letter ("The Tan Sheet" July 20, p. 17). The Swiss consortium includes the private partnership bank Lombard Odier, which manages a nutrition fund, Pharmanex notes. The new capital also will help support additional R&D efforts at the firm, as well as additional marketing support for all Pharmanex dietary supplements...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel